Atricure reports third quarter 2021 financial results

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in treatments for atrial fibrillation (afib) and left atrial appendage (laa) management, today announced third quarter 2021 financial results. “our results were driven by strong growth across key product lines, including the addition of new cryo nerve block and hybrid af™ therapy accounts, providing further validation of demand across our business,” said michael carrel, president and chief executive officer of atri
ATRC Ratings Summary
ATRC Quant Ranking